Johnson & Johnson announced the acquisition of heart disease medical device maker V-Wave in a deal worth up to $1.7 billion. Announced Tuesday, the transaction involves J&J paying $600 million upfront ...

Johnson & Johnson announced Aug. 20 it entered into a definitive agreement to acquire V-Wave Ltd., a privately held company that develops treatment options for heart failure. Under the terms of the ...

The RELIEVE-HF trial of the Ventura® Shunt System includes patients with reduced and preserved left ventricular function etiologies for heart failure CAESAREA, Israel, Oct. 24, 2022 /PRNewswire/ -- ...

Johnson & Johnson (NYSE:JNJ) has agreed to acquire medical device company V-Wave for an upfront payment of $600M. The deal also includes the potential for additional regulatory and commercial ...

I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave ...

V-Wave’s Ventura® Interatrial Shunt (IAS) is a novel implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure by creating a shunt between the left and ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson 1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...